SOST and prostate carcinoma: Treatment with recombinant SOST resulted in ~5.6-fold reduction in MALAT1 expression (Figure 4B), suggesting that Sost in the tumor microenvironment may have an inhibitory effect on MALAT1 and down-regulation of Sost in the bone microenvironment may enhance MALAT1 expression in prostate cancer.